omnibus
发表于 2025-3-25 03:32:48
http://reply.papertrans.cn/19/1900/189905/189905_21.png
亵渎
发表于 2025-3-25 09:06:47
http://reply.papertrans.cn/19/1900/189905/189905_22.png
xanthelasma
发表于 2025-3-25 12:12:09
Niels Bugert,Maximilian Schöpfel research due to its typical poor outcome. Besides a small subset of patients who can enjoy long-term disease-frees urvival through non-myeloablative allogenic stem cell transplant, most patients relapse and become frequently over time chemoresistant to conventional or high-dose cytotoxic-based ther
orthopedist
发表于 2025-3-25 18:13:45
http://reply.papertrans.cn/19/1900/189905/189905_24.png
Favorable
发表于 2025-3-25 20:14:46
Logistik in Wissenschaft und Praxis only applicable to approximately 20% of patients. Standard dose chemotherapy has included melphalan with dexamethasone. This regimen results in response rates in excess of 50%. With the introduction of IMID therapy, the combination of thalidomide or lenalidomide with dexamethasone has produced resp
FIG
发表于 2025-3-26 03:33:18
http://reply.papertrans.cn/19/1900/189905/189905_26.png
bizarre
发表于 2025-3-26 07:43:29
https://doi.org/10.1007/978-3-7643-8948-2Bortezomib; Cancer therapy; Multiple Myeloma; Oncology; Pharmacology; Proteasome inhibitors; Velcade; Apopt
upstart
发表于 2025-3-26 09:15:40
Springer Basel AG 2011
懒惰民族
发表于 2025-3-26 16:21:54
http://reply.papertrans.cn/19/1900/189905/189905_29.png
同步左右
发表于 2025-3-26 17:23:10
http://reply.papertrans.cn/19/1900/189905/189905_30.png